Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 27Uveal Melanoma 7Neoplasms 3Skin Neoplasms 2Urologic Neoplasms 1Neoplasm Metastasis 1Eye Neoplasms 1Carcinoma, Renal Cell 1

Interventions

montanide ISA 51 2Interleukin-2 2binimetinib 1belinostat 1Vincristine 1Tramadol 1Topotecan 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Proton Therapy 1Peptides 1Melphalan 1Magnetic Resonance Spectroscopy 1MART-1 Antigen 1MAGEA3 protein, human 1Leuprolide 1Lasers 1Laparotomy 1Ibuprofen 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eye Enucleation 1Etoposide 1Doxorubicin 1D-methadone 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Eye Neoplasms × MART-1 Antigen × Clear all
NCT00020475 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Completed
Dermatologic

Uveal Melanoma, Eye Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡